Angiotensin Converting Enzymes (ACE) Inhibitors Market Insights
Angiotensin converting enzymes inhibitors are used to for the treatment of various medical conditions such as hypertension, coronary artery disease, heart failure, diabetes, chronic kidney diseases, scleroderma, and migraines. Frequently prescribed angiotensin converting enzyme (ACE) inhibitors are benazepril, perindopril, trandolapril, captopril, enalaopril, lisinopril, and ramipril. ACE inhibitors are the first choice drugs for the treatment of hypertension.
The global angiotensin converting enzymes (ACE) inhibitors market was valued at US$ 11,693.6 million in 2017, and is expected to witness a CAGR of 0.8% during the forecast period (2018 – 2026).
Figure 1. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Value Analysis (US$ Mn) and Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of hypertension is expected to drive growth of the angiotensin converting enzymes (ACE) inhibitors market
Increasing prevalence of hypertension is one of the major drivers for the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, according to World Health Organization’s (WHO) report, in 2018, around 207 million people including 112 million men and 95 million women suffer from hypertension, annually in India.
Moreover, increasing number of research and development activities for improvement of cardiovascular functions during pregnancy is expected to propel the angiotensin converting enzyme (ACE) inhibitors market growth. For instance, in September 2018, Manchester University NHS Foundation Trust initiated clinical Phase II study of Enalapril Maleate for the pre-eclampsia condition. This study is for evaluating drug safety and efficacy on the patients. Pre-eclampsia condition is a pregnancy complication characterized by high blood pressure. It has various signs and symptoms including proteinuria, upper abdominal pain, and shortness of breath.
Angiotensin Converting Enzymes (ACE) Inhibitors Market - Regional Analysis
Regional segmentation of the global angiotensin converting enzymes (ACE) inhibitors market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America angiotensin converting enzymes (ACE) inhibitors market is expected to account for the largest market share, owing increasing approval activities by the U.S. Food and Drug Administration (FDA). For instance, in August 2016, Silvergate Pharmaceutical Inc. received the U.S. FDA approval for its Qbrelis, containing Lisinopril, an oral solution 1 mg/ml. This drug is indicated for the treatment of hypertension in adult and in children.
Moreover, Europe is expected to gain significant share in the global angiotensin converting enzymes (ACE) inhibitors market over the forecast period, owing to increasing product launch in this region. For instance, in September 2012, France-based Ceva Sante Animale S. A. launched its new combination drug, Benazepril and Spironolactone Tablet, for the treatment of heart failure in humans as well as in dogs.
Asia Pacific is also expected to witness significant growth in the angiotensin converting enzymes (ACE) inhibitors market over the forecast period, owing to increasing awareness activities regarding hypertension and its prevention in this region. For instance, in May 2018, Indian Council of Medical Research (ICMR) organized an awareness campaign on hypertension in collaboration with Public Health Foundation of India. According to ICMR, around 10.8% deaths annually caused by hypertension in India. Therefore, such programs will help to increase awareness for the treatment and management of hypertension, thereby supporting the ACE inhibitors market growth in this region.
Figure 2: Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Value (US$ Mn), By Region, 2018
Source: Coherent Market Insights Analysis (2019)
Angiotensin Converting Enzymes (ACE) Inhibitors Market - Competitive Landscape
Key players operating in the angiotensin converting enzymes (ACE) inhibitors market include, Pfizer, Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company, and Bayer AG.
Angiotensin converting enzymes (ACE) inhibitors act by inhibiting the angiotensin converting enzyme (ACE), which is an important component of renin angiotensin system. ACE inhibitors reduce the formation of angiotensin II and facilitate the dilation of blood vessels as well as reduce blood pressure. Angiotensin converting enzyme inhibitors also reduce blood pressure in kidneys. Angiotensin converting enzymes inhibitors (ACE) are effective for the treatment of congestive heart failure, stroke, and high blood pressure. However, overdose of ACE inhibitors may cause kidney failure, allergic reactions, angioedema, and neutropenia.
Increasing research and development activities related to study of ACE inhibitors is expected to boost the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, in February 2016, Monia Lorini, in collaboration with Istituto Di Ricerche Farmacologiche Mario Negri initiated clinical phase II study of ACE inhibitors (Lisinopril) for the treatment of extracapillary glomerulonephritis. This study is for evaluating drug safety and efficacy on the patients. It is expected to complete in December 2019.
Furthermore, in June 2014, Cardiology Research UBC initiated clinical trial phase IV to study the effects of statin including Rosuvastatin and Ramipril - angiotensin converting enzymes inhibitors such as Ramipril on coronary flow reserve and microcirculatory resistance in patients with coronary artery dissection. This study is expected to complete in June 2021.
Overdose of angiotensin converting enzyme (ACE) inhibitors is a major factor restraining growth of the ACE inhibitors market. Overdose of ACE inhibitors may lead to various side effects such as dry cough, hyperkalemia (increased blood potassium level), dizziness, headache, and fatigue. Overdose of ACE inhibitors may also cause cancer. For instance, in October 2018, according to Medical Press (medical center in Melbourne, Australia), angiotensin converting enzymes (ACE) inhibitors are used for the treatment of high blood pressure. However, overdose of ACE inhibitors can increases the risk of lung cancer in patients. These drugs are responsible for the excessive production of bradykinin in the lungs. Excessive bradykinin is the main cause of lung cancer.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 29 market data tables and 25 figures on “Angiotensin Converting Enzymes (ACE) Inhibitors Market” - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.